ERIN PILLETTE: Open Payments
NPI 1336743608 · SAINT CHARLES, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,642 in 25 payments from 10 companies in 2025. Trend: 2023 $37 · 2024 $613 · 2025 $1,642
Food & beverage: $1,132Consulting: $510
| Company | Payments | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. | 7 | $838 |
| GlaxoSmithKline, LLC. | 2 | $246 |
| AstraZeneca Pharmaceuticals LP | 3 | $159 |
| ARGENX US, INC. | 5 | $151 |
| Biogen, Inc. | 1 | $110 |
| Lundbeck LLC | 3 | $56 |
| Gilead Sciences, Inc. | 1 | $26 |
| Eisai Inc. | 1 | $25 |
| Lilly USA, LLC | 1 | $18 |
| Amgen Inc. | 1 | $14 |
Products named: ULTOMIRIS, NUCALA, SAPHNELO, TYSABRI, VYVGART, VYEPTI, VYVGART HYTRULO, Leqembi.
Industry payments across MO — which companies pay providers there.
